MEDIA RELEASE

# Viral Vector Manufacturing Facility (VVMF) and Gene2Cure enters strategic collaboration

- Enters strategic collaboration to jointly promote the use of Advanced Therapy Medicinal Products (ATMPs).
- Jointly promotes the use of ATMPs in the treatment of rare diseases for Australian and global markets.

JOINT RELEASE with Gene2Cure

**Sydney, Australia, 18 November 2026**

Viral Vector Manufacturing Facility Pty Ltd (**VVMF**), Australia's first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), and **Gene2Cure Foundation,** a US-based non-profit organisation dedicated to the development, translation and clinical implementation of experimental gene therapies for incurable rare and ultra-rare genetic conditions affecting children, have co-signed a **memorandum of understanding (MoU)** to jointly promote the use of Advanced Therapy Medicinal Products (ATMPs) in the treatment of rare diseases for Australian and global markets.

The MoU affirms a shared focus on building national capabilities and advancing sector growth in Australia, improving access for Australian and international patients.



Image: VVMF scientist working within the company's viral vector manufacturing facility in Sydney, Australia. Photo credit: VVMF

**Stephen Thompson, Chief Executive Officer of VVMF, said:** "Patients living with rare diseases often face limited treatment options and long journeys to access promising new therapies. Through our collaboration with Gene2Cure, VVMF aims to help increase access to advanced therapies for Australian patients while strengthening the local ecosystem needed to develop, manufacture and deliver these treatments. By working together, we can help build Australia's capability in cell and gene therapies and create new opportunities to improve the lives of patients both locally and globally."

**Prof. Leszek Lisowski, co-Founder and President, Gene2Cure Foundation, said:** "At Gene2Cure Foundation, our mission is to bring safe and effective gene therapies to children affected by rare and ultra-rare genetic diseases, while challenging the traditional timelines and costs associated with their development. Because our work is made possible by the generosity of philanthropic foundations and individual donors, we have a responsibility to ensure that every dollar is used as effectively as possible, without ever compromising scientific quality or patient safety. Although Gene2Cure is US-based, our operations in Australia and partnerships across the global gene therapy ecosystem allow us to access world-class expertise and infrastructure wherever they offer the greatest value. Our collaboration with VVMF is an important step in this strategy, helping us accelerate the development and manufacturing of high-quality experimental therapies in a time- and cost-efficient manner, ultimately bringing much-needed treatments closer to the children and families who are waiting for them"

ATMPs are innovative medicines based on genes, cells, or tissue engineering. They are often complex, based on cutting-edge science involving living cells, and require specialised manufacturing capabilities and a highly skilled workforce. ATMPs offer new treatments or cures for various diseases, including cancer, neurodegenerative, and cardiovascular diseases.

**About VVMF – Unlocking the Future of Medicine**

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia's only Contract Development and Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and bio-pharma companies to accelerate the path to market for cell and gene therapies to local and global patients.

Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.

**Contact -** For further information please contact media@vvmf.com.au

**About Gene2Cure Foundation**

The Gene2Cure Foundation is a patient-centric non-profit organization focused on designing, developing, and deploying gene therapies to treat devastating, (ultra)rare paediatric genetic disorders. Through strategic ecosystem alliances with leading global CDMOs and research consortiums, Gene2Cure Foundation actively streamlines chemistry, manufacturing, and controls (CMC) timelines to advance programs like GAND, SLOS and PUS3 Syndrome from research-grade concepts into phase I/II human clinical trials. Discovery details and pipeline roadmaps are available at gene2cure.com.

Follow Gene2Cure on LinkedIn, Instagram, Facebook and YouTube.

**Contact -** For further information please contact info@gene2cure.com